Tag Archives: biosimilars

Global Biosimilars Market to Reach $2.4 Billion in 2013

By Guest Blogger | Published: May 17, 2013
By Adeline Siew, Editor, Pharmaceutical Technology Europe. The global market for biosimilar drugs has been forecasted to be worth $2.445 billion this year, according to a new report by British market research specialist Visiongain. The growth represents a 20% increase from last year and accounts for approximately 2% of the overall biologics market. Moreover, the global [...]
Posted in Biotech, Global, Guest Blog, R&D | Also tagged , , | Leave a comment

U.S. Biosimilars Under Threat?

By Guest Blogger | Published: April 27, 2012
by D’vorah Graeser, Graeser Associates International While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.
Posted in Biotech, FDA, Guest Blog, IP, Legal, Regulatory, Strategy, Technology | Also tagged , , | 1 Comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

By Ben Comer | Published: May 18, 2011
Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Posted in Agency Insight, Biotech, Emerging Markets, Europe, Strategy | Also tagged , | 2 Comments

Innovators: Take a Leaf from the Generic Industry Book

By Guest Blogger | Published: February 1, 2011
No-one can accuse the European generic industry of indolence. It supplies huge quantities of medicines to European healthcare suppliers — its volume is estimated at around a half of the market. It is accounting for a growing share of marketing authorization applications in Europe. And its industry association, the EGA, has turned it from being [...]
Posted in Europe, Regulatory, healthcare | Also tagged , , , , , , , | Leave a comment

MedImmune Bets Its Fate on “Biobetters”

By Walter Armstrong | Published: September 9, 2010
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy | Also tagged , , , , , | 1 Comment